IL156447A0 - Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors - Google Patents

Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors

Info

Publication number
IL156447A0
IL156447A0 IL15644701A IL15644701A IL156447A0 IL 156447 A0 IL156447 A0 IL 156447A0 IL 15644701 A IL15644701 A IL 15644701A IL 15644701 A IL15644701 A IL 15644701A IL 156447 A0 IL156447 A0 IL 156447A0
Authority
IL
Israel
Prior art keywords
dapd
combination therapy
inosine monophosphate
dehydrogenase inhibitors
monophosphate dehydrogenase
Prior art date
Application number
IL15644701A
Other languages
English (en)
Original Assignee
Triangle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triangle Pharmaceuticals Inc filed Critical Triangle Pharmaceuticals Inc
Publication of IL156447A0 publication Critical patent/IL156447A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15644701A 2000-12-15 2001-12-12 Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors IL156447A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25606800P 2000-12-15 2000-12-15
US27260501P 2001-03-01 2001-03-01
PCT/US2001/048817 WO2002068058A2 (en) 2000-12-15 2001-12-12 Dapd combination therapy with imdph inhibitors such as ribavirin or mycophenolic acid

Publications (1)

Publication Number Publication Date
IL156447A0 true IL156447A0 (en) 2004-01-04

Family

ID=26945133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15644701A IL156447A0 (en) 2000-12-15 2001-12-12 Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors

Country Status (12)

Country Link
US (2) US20020173491A1 (ja)
EP (1) EP1363704A2 (ja)
JP (1) JP2005500252A (ja)
KR (1) KR20040040402A (ja)
CN (1) CN1501828A (ja)
BR (1) BR0116223A (ja)
CA (1) CA2432287A1 (ja)
IL (1) IL156447A0 (ja)
MX (1) MXPA03005382A (ja)
OA (1) OA12588A (ja)
RU (1) RU2003121401A (ja)
WO (1) WO2002068058A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
WO2005003147A2 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP2619200A4 (en) * 2010-09-22 2014-10-15 Calcimedica Inc COMPOUNDS AS MODULATORS OF INTRA CELLULAR CALCIUM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US5932600A (en) * 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6511983B1 (en) * 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
CA2389745C (en) * 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues

Also Published As

Publication number Publication date
US20050113321A1 (en) 2005-05-26
WO2002068058A3 (en) 2003-09-04
US20020173491A1 (en) 2002-11-21
JP2005500252A (ja) 2005-01-06
OA12588A (en) 2006-06-08
RU2003121401A (ru) 2005-02-10
EP1363704A2 (en) 2003-11-26
WO2002068058A2 (en) 2002-09-06
CN1501828A (zh) 2004-06-02
MXPA03005382A (es) 2005-02-03
CA2432287A1 (en) 2002-09-06
BR0116223A (pt) 2006-01-31
KR20040040402A (ko) 2004-05-12

Similar Documents

Publication Publication Date Title
EG24027A (en) Pyrrolotriazine inhibitors of kinases
AU2001284564A1 (en) Nucleoside metabolism inhibitors
IL148719A0 (en) Kinase inhibitors as therapeutic agents
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
IL148614A0 (en) Pteridinones as kinase inhibitors
IL145764A0 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
HUP0303855A3 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
AU3704101A (en) Kinase inhibitors
AU6895801A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
PL363150A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU7526901A (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
AU3828301A (en) Novel sphingosine kinases
IL156447A0 (en) Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors
GB0030284D0 (en) Enzyme inhibitors
IL153575A0 (en) Uses for nad synthetase inhibitors
EP1135135A4 (en) CHK1 KINASE INHIBITORS
GB0021040D0 (en) Drills
AU2001269121A1 (en) Substituted amidoalkyl-uracils as parp inhibitors
AU4587901A (en) Bisubstrate inhibitors of kinases
AU2002230890A1 (en) Targeted enzyme prodrug therapy
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
GB0014861D0 (en) Novel telomerase inhibitors
GB9917217D0 (en) Scratcher
GB0014046D0 (en) Compounds useful in therapy
AU2003261114A1 (en) Combination therapy with 1,3-dioxolanes and inosine monophosphate dehydrogenase inhibitors